CORRECTION
Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Kumar Derebail V, et al., and on behalf of the DUET Study Group: DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol 29: 2745–2754, 2018.
The authors wish to make a correction to Supplemental Table 6: Change in Diuretic Treatment During the Double-blind Period (Full Analysis Set). The table is not published in the main manuscript and is available in the supplemental material found at: http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2018010091/-/DCSupplemental.
The new table is below:
| Irbesartan (N=36) | Sparsentan (N=73) | |
|---|---|---|
| All diuretics | ||
| New or Increased | 4 (11.1%) | 8 (11.0%) |
| Reduced | 1 (2.8%) | 1 (1.4%) |
| Thiazide[1] | ||
| New or Increased | 3 (8.3%) | 1 (1.4%) |
| Reduced | 0 (0%) | 1 (1.4%) |
| Loop[2] | ||
| New or Increased | 2 (5.6%) | 7 (9.6%) |
| Reduced | 1 (2.8%) | 0 (0%) |
The only change is a change in the number of “new or increased” loop diuretics from 1 (2.8%) to 2 (5.6%) which lessens the difference between the two groups. This change does not alter the conclusions from this table and does not impact any of the main findings or conclusions reported in the study.